Cargando…

Emerging treatment strategies for metastatic triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is often associated with an aggressive phenotype and a poor prognosis. Cytotoxic chemotherapy remains the mainstay of treatment for most patients with metastatic TNBC (mTNBC), but duration of response is often shor...

Descripción completa

Detalles Bibliográficos
Autores principales: Huppert, Laura A., Gumusay, Ozge, Rugo, Hope S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003656/
https://www.ncbi.nlm.nih.gov/pubmed/35422881
http://dx.doi.org/10.1177/17588359221086916
_version_ 1784686176783826944
author Huppert, Laura A.
Gumusay, Ozge
Rugo, Hope S.
author_facet Huppert, Laura A.
Gumusay, Ozge
Rugo, Hope S.
author_sort Huppert, Laura A.
collection PubMed
description Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is often associated with an aggressive phenotype and a poor prognosis. Cytotoxic chemotherapy remains the mainstay of treatment for most patients with metastatic TNBC (mTNBC), but duration of response is often short and median overall survival is only 12–18 months. Therefore, it is critical to identify novel treatment strategies to improve outcomes for these patients. In this review article, we discuss recent advances in treatment strategies for patients with mTNBC including the use of immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates. For each topic, we summarize important preclinical and clinical data, discuss implications for clinical practice, and highlight future research directions.
format Online
Article
Text
id pubmed-9003656
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-90036562022-04-13 Emerging treatment strategies for metastatic triple-negative breast cancer Huppert, Laura A. Gumusay, Ozge Rugo, Hope S. Ther Adv Med Oncol Review Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is often associated with an aggressive phenotype and a poor prognosis. Cytotoxic chemotherapy remains the mainstay of treatment for most patients with metastatic TNBC (mTNBC), but duration of response is often short and median overall survival is only 12–18 months. Therefore, it is critical to identify novel treatment strategies to improve outcomes for these patients. In this review article, we discuss recent advances in treatment strategies for patients with mTNBC including the use of immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates. For each topic, we summarize important preclinical and clinical data, discuss implications for clinical practice, and highlight future research directions. SAGE Publications 2022-04-07 /pmc/articles/PMC9003656/ /pubmed/35422881 http://dx.doi.org/10.1177/17588359221086916 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Huppert, Laura A.
Gumusay, Ozge
Rugo, Hope S.
Emerging treatment strategies for metastatic triple-negative breast cancer
title Emerging treatment strategies for metastatic triple-negative breast cancer
title_full Emerging treatment strategies for metastatic triple-negative breast cancer
title_fullStr Emerging treatment strategies for metastatic triple-negative breast cancer
title_full_unstemmed Emerging treatment strategies for metastatic triple-negative breast cancer
title_short Emerging treatment strategies for metastatic triple-negative breast cancer
title_sort emerging treatment strategies for metastatic triple-negative breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003656/
https://www.ncbi.nlm.nih.gov/pubmed/35422881
http://dx.doi.org/10.1177/17588359221086916
work_keys_str_mv AT huppertlauraa emergingtreatmentstrategiesformetastatictriplenegativebreastcancer
AT gumusayozge emergingtreatmentstrategiesformetastatictriplenegativebreastcancer
AT rugohopes emergingtreatmentstrategiesformetastatictriplenegativebreastcancer